Androgen Suppression Therapy and Radiation Therapy With or Without Docetaxel in Treating Patients With High-Risk Localized Prostate Cancer - Contacts and Locations

Androgen Suppression Therapy and Radiation Therapy With or Without Docetaxel in Treating Patients With High-Risk Localized Prostate Cancer

This study is currently recruiting participants.

Study NCT00651326. Last updated on September 22, 2008. Information provided by National Cancer Institute (NCI)

Please refer to this study by its ClinicalTrials.gov identifier: NCT00651326

Locations


Canada, Alberta
	Tom Baker Cancer Centre - Calgary	Recruiting
	Calgary, Alberta, Canada, T2N 4N2
	Contact: David P. Skarsgard 403-521-3164

Canada, British Columbia
	British Columbia Cancer Agency - Centre for the Southern Interior	Recruiting
	Kelowna, British Columbia, Canada, V1Y 5L3
	Contact: Susan Ellard 250-712-3922
	British Columbia Cancer Agency - Vancouver Cancer Centre	Recruiting
	Vancouver, British Columbia, Canada, V5Z 4E6
	Contact: Michael McKenzie 604-877-6000

Canada, Ontario
	Princess Margaret Hospital	Recruiting
	Toronto, Ontario, Canada, M5G 2M9
	Contact: Andrew J. Bayley 416-946-2919

Sponsors and Collaborators

National Cancer Institute of Canada

National Cancer Institute (NCI)

Investigators


Study Chair:	Michael R. McKenzie, MD, FRCPC	British Columbia Cancer Agency

Investigator:	Kim N. Chi, MD	British Columbia Cancer Agency